315 related articles for article (PubMed ID: 24569074)
1. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
[TBL] [Abstract][Full Text] [Related]
3. Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D; Mohaghegh M
J Biomol Screen; 2014 Apr; 19(4):547-55. PubMed ID: 24297044
[TBL] [Abstract][Full Text] [Related]
4. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
6. Isolation of a novel neutralizing antibody fragment against human vascular endothelial growth factor from a phage-displayed human antibody repertoire using an epitope disturbing strategy.
Lamdan H; Ayala M; Rojas G; Munoz Y; Morera Y; Guirola O; Chinea G; Gavilondo JV
J Biotechnol; 2011 Jan; 151(2):166-74. PubMed ID: 21167224
[TBL] [Abstract][Full Text] [Related]
7. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
8. Nanoantibodies for detection and blocking of bioactivity of human vascular endothelial growth factor A(165).
Tillib SV; Ivanova TI; Lyssuk EY; Larin SS; Kibardin AV; Korobko EV; Vikhreva PN; Gnuchev NV; Georgiev GP; Korobko IV
Biochemistry (Mosc); 2012 Jun; 77(6):659-65. PubMed ID: 22817466
[TBL] [Abstract][Full Text] [Related]
9. Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.
Ebrahimizadeh W; Mousavi Gargari SL; Javidan Z; Rajabibazl M
Appl Biochem Biotechnol; 2015 Aug; 176(7):1985-95. PubMed ID: 26054617
[TBL] [Abstract][Full Text] [Related]
10. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
11. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.
Naderi S; Roshan R; Ghaderi H; Behdani M; Mahmoudi S; Habibi-Anbouhi M; Shokrgozar MA; Kazemi-Lomedasht F
Mol Immunol; 2020 Dec; 128():56-63. PubMed ID: 33070092
[TBL] [Abstract][Full Text] [Related]
12. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.
Karami E; Sabatier JM; Behdani M; Irani S; Kazemi-Lomedasht F
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1233-1239. PubMed ID: 32441172
[TBL] [Abstract][Full Text] [Related]
13. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
Sadeghi A; Behdani M; Muyldermans S; Habibi-Anbouhi M; Kazemi-Lomedasht F
Drug Test Anal; 2020 Jan; 12(1):92-100. PubMed ID: 31476257
[TBL] [Abstract][Full Text] [Related]
14. A novel nanobody against urease activity of Helicobacter pylori.
Ardekani LS; Gargari SL; Rasooli I; Bazl MR; Mohammadi M; Ebrahimizadeh W; Bakherad H; Zare H
Int J Infect Dis; 2013 Sep; 17(9):e723-8. PubMed ID: 23561799
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
[TBL] [Abstract][Full Text] [Related]
16. Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.
Kazemi-Lomedasht F; Behdani M; Rahimpour A; Habibi-Anbouhi M; Poshang-Bagheri K; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):201-5. PubMed ID: 26090598
[TBL] [Abstract][Full Text] [Related]
17. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
[TBL] [Abstract][Full Text] [Related]
18. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.
Zhang J; Li H; Wang X; Qi H; Miao X; Zhang T; Chen G; Wang M
Biotechnol Prog; 2012 Jul; 28(4):981-9. PubMed ID: 22581629
[TBL] [Abstract][Full Text] [Related]
19. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.
Lamdan H; Gavilondo JV; Muñoz Y; Pupo A; Huerta V; Musacchio A; Pérez L; Ayala M; Rojas G; Balint RF; Larrick JW
Mol Biosyst; 2013 Aug; 9(8):2097-106. PubMed ID: 23702826
[TBL] [Abstract][Full Text] [Related]
20. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
Lu D; Shen J; Vil MD; Zhang H; Jimenez X; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2003 Oct; 278(44):43496-507. PubMed ID: 12917408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
